Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | CTSD | P07339 | 2/20 | 0.37 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.37 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.35 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | CPA1 | P15085 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1758553 | 0.90 | CA1 (0.50) | CA2CA1HIF1AMEN1KMT2A | |
| SCHEMBL8047201 | 0.83 | CA1 (0.45) | CA2CA1HIF1AMEN1KMT2A | |
| SCHEMBL28937194 | 0.77 | FOLH1 (0.54) | CA2CA1MEN1KMT2AUSP2 | |
| SCHEMBL8530894 | 0.77 | MEN1 (0.38) | CA2MEN1KMT2ASLC1A3SLC1A2 | |
| SCHEMBL8047199 | 0.76 | CA2 (0.35) | CA2CA1MEN1KMT2ACTSD | |
| SCHEMBL8529431 | 0.75 | TSHR (0.41) | MEN1KMT2AUSP2TSHRMME | |
| SCHEMBL10052282 | 0.75 | CA1 (0.52) | CA2CA1HIF1AKMT2ACTSD | |
| Ethylmalonate SCHEMBL107241 | 0.74 | — | — | |
| SCHEMBL8174142 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL5318804 | 0.73 | CA1 (0.50) | CA2CA1HIF1AKMT2ACTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022270554-A1 | COSMETIC COMPOSITION | 味の素株式会社 | 2022-12-29 | — | — | WO | disclosed |
| WO-2021115375-A1 | NITROGEN-CONTAINING HETEROCYCLIC AUTOTAXIN INHIBITOR, AND COMPOSITION CONTAINING SAME AND USE THEREOF | 四川海思科制药有限公司 | 2021-06-17 | — | — | WO | disclosed |
| EP-3262044-B1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | MAX DELBRUECK CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2019-02-06 | — | — | EP | disclosed |
| US-20180051025-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2018-02-22 | — | — | US | disclosed |
| EP-3262044-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2018-01-03 | — | — | EP | disclosed |
| WO-2016135199-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2016-09-01 | — | — | WO | disclosed |
| EP-3061761-A1 | Xanthine derivatives, their use as a medicament, and pharmaceutical preparations comprising the same | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2016-08-31 | — | — | EP | disclosed |
| EP-2889289-A1 | Pyridazine-dione N-substituted glycine derivatives as HIF hydroxylase inhibitors | GlaxoSmithKline LLC (US) | 2015-07-01 | — | — | EP | disclosed |
| US-RE44613-E1 | N-substituted glycine derivatives: hydroxylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2013-11-26 | — | — | US | disclosed |
| EP-2227466-B1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AG (DE) | 2011-04-20 | — | — | EP | disclosed |
| US-20110021670-A1 | INTEGRATED PROCESS FOR MANUFACTURING A BINDER | SOIL NET LLC (US) | 2011-01-27 | — | — | US | disclosed |
| EP-2227466-A2 | HETEROARYL-SUBSTITUTED PIPERIDINES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2010-09-15 | — | — | EP | disclosed |
| EP-2124565-A2 | N-SUBSTITUTED GLYCINE DERIVATIVES: HYDROXYLASE INHIBITORS | Smithkline Beecham Corporation (US) | 2009-12-02 | — | — | EP | disclosed |
| US-7608621-B2 | Such as n-{[2-[(4-bromo-2-fluorophenyl)methyl]-5-hydroxy-6-(1-methylethyl)-3-oxo-2,3-dihydro-4-pyridazinyl]carbonyl}glycine; anemia; increasing erythropoietin production | SMITHKLINE BEECHAM, CORP. (US) | 2009-10-27 | — | — | US | disclosed |
| WO-2009068214-A2 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-04 | — | — | WO | disclosed |
| US-20080214549-A1 | N-Substituted Glycine Derivatives: Hydroxylase Inhibitors | GLAXOSMITHKLINE LLC | 2008-09-04 | — | — | US | disclosed |
| WO-2008089052-A2 | N-SUBSTITUTED GLYCINE DERIVATIVES: HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-24 | — | — | WO | disclosed |
| EP-1888597-A2 | ANTIBACTERIAL AGENTS | Warner-Lambert Company LLC (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006120563-A2 | ANTIBACTERIAL AGENTS | WARNER-LAMBERT COMPANY LLC (US) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180051025-A1 | XANTHINE DERIVATIVES, THEIR USE AS A MEDICAMENT, AND PHARMACEUTICAL PREPARATIONS COMPRISING THE SAME | TPH1, XDH, TPH2 | CA2 2060/4885CA1 3021/4885HIF1A 1238/4885 |
| US-20080214549-A1 | N-Substituted Glycine Derivatives: Hydroxylase Inhibitors | EGLN2, EGLN3, HIF1AN | CA2 1108/4885CA1 2879/4885HIF1A 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.